Reason for request
New indication
Clinical Benefit
| Insufficient |
The Committee deems that the clinical benefit of LIBTAYO (cemiplimab) in association with a platinum salt-based chemotherapy regimen, is insufficient in the MA indication to justify public funding. |
Clinical Added Value
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
Zy7pP83fHjQH0zGp
